비교리스트

 카트 문의
시장보고서
상품코드
1671178

세계의 피부과 치료제 시장 규모, 점유율, 동향, 업계 분석 : 치료별, 종류별, 투여 경로별, 유통 채널별, 약물 종류별, 지역별 - 시장 예측(2025-2034년)

Dermatology Drugs Market Size, Share, Trends, Industry Analysis Report: By Therapy, Type, Route of Administration, Distribution Channel, Drug Class, and Region - Market Forecast, 2025-2034
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 119 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 피부과 치료제 시장 규모는 2034년까지 661억 5,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.

피부과 치료제 시장의 성장은 여드름, 건선, 습진, 피부암과 같은 피부 질환의 유병률 증가와 치료 옵션의 발전이 주요 원동력이 되고 있습니다. 특히 만성 및 중증 피부질환에 대한 생물학적 제제 및 표적 치료제에 대한 수요 증가와 피부 건강에 대한 인식이 높아지는 것이 주요 촉진요인으로 꼽힙니다. 피부과 치료제의 시장 기회는 일반의약품(OTC)의 확대와 유전자 검사를 활용한 맞춤형 피부과 치료로의 전환에 있습니다.

미용 피부과 치료의 증가, 외용제 처방의 혁신, 환자 참여도 향상을 위한 디지털 헬스 솔루션의 통합 등의 트렌드가 시장을 형성하고 있습니다. 이러한 첨단 치료법의 도입과 신흥 시장에서의 의료 접근성 증가로 인해 피부과 치료제 시장은 지속적인 성장이 예상됩니다.

피부과 치료제 시장 : 분석 개요

치료별로는 여드름 치료 분야가 피부과 치료제 시장 매출에서 가장 큰 비중을 차지하고 있습니다. 이는 여드름의 높은 유병률, 특히 10대와 젊은 성인들 사이에서 여드름의 유병률이 높고, 외용제 및 경구용 치료제가 널리 사용되고 있기 때문입니다. 건선 역시 중요한 분야로, 생물학적 제제 및 표적 치료제의 채택이 강력한 성장을 주도하고 있습니다.

건선, 습진 등 만성 피부질환은 전문적인 치료가 필요하기 때문에 처방약이 피부과 치료제의 시장 점유율을 독식하고 있습니다. 일반의약품(OTC) 분야는 접근성이 좋고 비용 효율적인 셀프케어를 선호하는 소비자들이 증가하면서 빠르게 성장하고 있습니다.

투여 경로별로는 많은 피부 질환의 1차 치료제로서 외용제가 가장 큰 점유율을 차지하고 있습니다. 경구제 부문은 특히 새로운 경구용 생물학적 제제의 도입과 여드름, 건선 등의 전신 치료제로 인해 가장 높은 성장세를 보이고 있습니다.

유통 채널별로는 병원 약국 부문이 가장 큰 시장 점유율을 차지하고 있으며, 이는 주로 중증 피부 질환에 대한 전문적인 치료 수요에 기인합니다. 소매 약국 부문은 OTC 피부과 제품에 대한 수요 증가와 이러한 치료에 대한 소비자의 접근성 확대로 인해 가장 빠르게 성장하고 있는 부문입니다.

북미는 선진화된 의료 시스템, 높은 피부과 인지도, 제약사의 강력한 시장 입지를 바탕으로 피부과 치료제 세계 시장 점유율을 독점하고 있습니다. 아시아태평양은 의료 접근성 증가, 인지도 향상, 피부과 치료에 대한 수요 증가로 인해 가장 빠르게 성장하고 있는 지역입니다.

피부과 치료제 시장의 주요 기업으로는 AbbVie, Eli Lilly and Company, Johnson & Johnson, Novartis, GlaxoSmithKline, Amgen, Pfizer, Sanofi, Bayer, Merck & Co., UCB, Bristol-Myers Squibb, L'Oreal, Galderma, and Meda Pharmaceuticals. 등이 있습니다.

목차

제1장 소개

제2장 주요 요약

제3장 분석 방법

제4장 세계의 피부과 치료제 시장 인사이트

  • 시장 현황
  • 피부과 치료제 시장 역학
    • 성장 촉진요인과 기회
      • 피부과의 생물학적 제제 수요 증가
      • 외용 치료제와 일반의약품(OTC)으로의 전환
    • 성장 억제요인과 과제
      • 피부과 치료제의 고액의 비용
  • PESTLE 분석
  • 피부과 치료제 시장 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 피부과 치료제 시장 : 치료별

  • 주요 분석 결과
  • 소개
  • 여드름
  • 건선
  • 주사
  • 탈모
  • 기타

제6장 세계의 피부과 치료제 시장 : 종류별

  • 주요 분석 결과
  • 처방전
  • 일반의약품(OTC)

제7장 세계의 피부과 치료제 시장 : 투여 경로별

  • 주요 분석 결과
  • 소개
  • 국소
  • 경구
  • 비경구

제8장 세계의 피부과 치료제 시장 : 유통 채널별

  • 주요 분석 결과
  • 소개
  • 병원 약국
  • 소매 약국
  • 기타

제9장 세계의 피부과 치료제 시장 : 약물 종류별

  • 주요 분석 결과
  • 소개
  • 항감염제
  • 코르티코스테로이드
  • 여드름 예방
  • 칼시뉴린 억제제
  • 레티노이드
  • 기타

제10장 세계의 피부과 치료제 시장 : 지역별

  • 주요 분석 결과
  • 소개
    • 피부과 치료제 시장 평가 : 지역별(2020-2034년)
  • 북미
    • 북미 : 치료별(2020-2034년)
    • 북미 : 종류별(2020-2034년)
    • 북미 : 투여 경로별(2020-2034년)
    • 북미 : 유통 채널별(2020-2034년)
    • 북미 : 약물 종류별(2020-2034년)
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 치료별(2020-2034년)
    • 유럽 : 종류별(2020-2034년)
    • 유럽 : 투여 경로별(2020-2034년)
    • 유럽 : 유통 채널별(2020-2034년)
    • 유럽 : 약물 종류별(2020-2034년)
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 치료별(2020-2034년)
    • 아시아태평양 : 종류별(2020-2034년)
    • 아시아태평양 : 투여 경로별(2020-2034년)
    • 아시아태평양 : 유통 채널별(2020-2034년)
    • 아시아태평양 : 약물 종류별(2020-2034년)
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 치료별(2020-2034년)
    • 중동 및 아프리카 : 종류별(2020-2034년)
    • 중동 및 아프리카 : 투여 경로별(2020-2034년)
    • 중동 및 아프리카 : 유통 채널별(2020-2034년)
    • 중동 및 아프리카 : 약물 종류별(2020-2034년)
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 남아프리카공화국
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 치료별(2020-2034년)
    • 라틴아메리카 : 종류별(2020-2034년)
    • 라틴아메리카 : 투여 경로별(2020-2034년)
    • 라틴아메리카 : 유통 채널별(2020-2034년)
    • 라틴아메리카 : 약물 종류별(2020-2034년)
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제11장 경쟁 구도

  • 사업 확대·기업 인수 분석
    • 사업 확대
    • 기업 인수
  • 제휴/협업/합의/공개

제12장 기업 개요

  • AbbVie
  • Amgen
  • Bayer
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Galderma
  • GlaxoSmithKline
  • Johnson & Johnson
  • L'Oreal
  • Meda Pharmaceuticals
ksm 25.04.01

The dermatology drugs market size is expected to reach USD 66.15 billion by 2034, according to a new study by Polaris Market Research. The report "Dermatology Drugs Market Size, Share, Trends, Industry Analysis Report: By Therapy (Acne, Psoriasis, Rosacea, Alopecia, and Others), Type, Route of Administration, Distribution Channel, Drug Class, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The dermatology drugs market growth is significantly driven by an increasing prevalence of skin conditions, such as acne, psoriasis, eczema, and skin cancer, coupled with advancements in treatment options. Key drivers include the rising demand for biologics and targeted therapies, particularly for chronic and severe skin diseases, as well as the growing awareness about skin health. Dermatology drugs market opportunities exist in the expansion of over-the-counter (OTC) products and the increasing shift toward personalized dermatology treatments, leveraging genetic testing for more tailored care.

Trends such as the rise in aesthetic dermatology treatments, innovations in topical drug formulations, and the integration of digital health solutions for improved patient engagement are shaping the market. With the growing adoption of these advanced treatments and increasing healthcare access in emerging markets, the dermatology drugs market is poised for continued growth.

Dermatology Drugs Market Report Highlights:

Based on therapy, the acne therapy segment holds the largest share of the dermatology drugs market revenue due to the high prevalence of acne, especially among teens and young adults, and the widespread use of topical and oral treatments. Psoriasis is also a significant segment, with strong growth driven by the adoption of biologics and targeted therapies.

The prescription drugs segment, by type, dominates the dermatology drugs market share due to the need for specialized treatments for chronic skin conditions, such as psoriasis and eczema. The over-the-counter (OTC) segment is growing rapidly, driven by increasing consumer preference for accessible, cost-effective self-care solutions.

In terms of route of administration, the topical segment holds the largest share, as it is the first-line treatment for many skin conditions. The oral segment is registering the highest growth, especially with the introduction of new oral biologics and systemic treatments for conditions such as acne and psoriasis.

The hospital pharmacies segment, by distribution channel, holds the largest market share, primarily due to the demand for specialized treatments for severe dermatological conditions. The retail pharmacies segment is the fastest-growing segment, driven by the increasing demand for OTC dermatology products and greater consumer access to these treatments.

North America dominates the global dermatology drugs market share due to advanced healthcare systems, high dermatology awareness, and strong market presence of pharmaceutical companies. Asia Pacific is the fastest-growing region, driven by increasing healthcare access, rising awareness, and growing demand for dermatology treatments.

A few key players in the dermatology drugs market are AbbVie, Eli Lilly and Company, Johnson & Johnson, Novartis, GlaxoSmithKline, Amgen, Pfizer, Sanofi, Bayer, Merck & Co., UCB, Bristol-Myers Squibb, L'Oreal, Galderma, and Meda Pharmaceuticals.

Polaris Market Research has segmented the dermatology drugs market report on the basis of therapy, type, route of administration, distribution channel, drug class, and region:

By Therapy Outlook (Revenue - USD Billion, 2020-2034)

  • Acne
  • Psoriasis
  • Rosacea
  • Alopecia
  • Others

By Type Outlook (Revenue - USD Billion, 2020-2034)

  • Prescription
  • Over-the-Counter (OTC)

By Route of Administration Outlook (Revenue - USD Billion, 2020-2034)

  • Topical
  • Oral
  • Parenteral

By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Drug Class Outlook (Revenue - USD Billion, 2020-2034)

  • Anti-Infectives
  • Corticosteroids
  • Anti-Acne
  • Calcineurin Inhibitors
  • Retinoids
  • Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Dermatology Drugs Market Insights

  • 4.1. Dermatology Drugs Market - Frequency Snapshot
  • 4.2. Dermatology Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Growing Demand for Biologics in Dermatology
      • 4.2.1.2. Shift Toward Topical Treatments and Over-the-Counter (OTC) Products
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Dermatology Drugs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Dermatology Drugs Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Dermatology Drugs Market, by Therapy

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
  • 5.3. Acne
    • 5.3.1. Global Dermatology Drugs Market, Acne, by Region, 2020-2034 (USD Billion)
  • 5.4. Psoriasis
    • 5.4.1. Global Dermatology Drugs Market, by Psoriasis, by Region, 2020-2034 (USD Billion)
  • 5.5. Rosacea
    • 5.5.1. Global Dermatology Drugs Market, by Rosacea, by Region, 2020-2034 (USD Billion)
  • 5.6. Alopecia
    • 5.6.1. Global Dermatology Drugs Market, by Alopecia, by Region, 2020-2034 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Dermatology Drugs Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Dermatology Drugs Market, by Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
  • 6.3. Prescription
    • 6.3.1. Global Dermatology Drugs Market, by Prescription, by Region, 2020-2034 (USD Billion)
  • 6.4. Over-the-Counter (OTC)
    • 6.4.1. Global Dermatology Drugs Market, by Over-the-Counter (OTC), by Region, 2020-2034 (USD Billion)

7. Global Dermatology Drugs Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • 7.3. Topical
    • 7.3.1. Global Dermatology Drugs Market, by Topical, by Region, 2020-2034 (USD Billion)
  • 7.4. Oral
    • 7.4.1. Global Dermatology Drugs Market, Oral, by Region, 2020-2034 (USD Billion)
  • 7.5. Parenteral
    • 7.5.1. Global Dermatology Drugs Market, Parenteral, by Region, 2020-2034 (USD Billion)

8. Global Dermatology Drugs Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.3. Hospital Pharmacies
    • 8.3.1. Global Dermatology Drugs Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 8.4. Retail Pharmacies
    • 8.4.1. Global Dermatology Drugs Market, by Retail Pharmacies, by Region, 2020-2034 (USD Billion)
  • 8.5. Others
    • 8.5.1. Global Dermatology Drugs Market, by Others, by Region, 2020-2034 (USD Billion)

9. Global Dermatology Drugs Market, by Drug Class

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Global Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • 9.3. Anti-Infectives
    • 9.3.1. Global Dermatology Drugs Market, by Anti-Infectives, by Region, 2020-2034 (USD Billion)
  • 9.4. Corticosteroids
    • 9.4.1. Global Dermatology Drugs Market, by Corticosteroids, by Region, 2020-2034 (USD Billion)
  • 9.5. Anti-Acne
    • 9.5.1. Global Dermatology Drugs Market, by Anti-Acne, by Region, 2020-2034 (USD Billion)
  • 9.6. Calcineurin Inhibitors
    • 9.6.1. Global Dermatology Drugs Market, by Calcineurin Inhibitors, by Region, 2020-2034 (USD Billion)
  • 9.7. Retinoids
    • 9.7.1. Global Dermatology Drugs Market, by Retinoids, by Region, 2020-2034 (USD Billion)
  • 9.8. Others
    • 9.8.1. Global Dermatology Drugs Market, by Others, by Region, 2020-2034 (USD Billion)

10. Global Dermatology Drugs Market, by Geography

  • 10.1. Key Findings
  • 10.2. Introduction
    • 10.2.1. Dermatology Drugs Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 10.3. Dermatology Drugs Market - North America
    • 10.3.1. North America: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
    • 10.3.2. North America: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
    • 10.3.3. North America: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.3.4. North America: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 10.3.5. North America: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.3.7. Dermatology Drugs Market - U.S.
      • 10.3.7.1. U.S.: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.3.7.2. U.S.: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.3.7.3. U.S.: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.3.7.4. U.S.: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.3.7.5. U.S.: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.3.8. Dermatology Drugs Market - Canada
      • 10.3.8.1. Canada: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.3.8.2. Canada: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.3.8.3. Canada: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.3.8.4. Canada: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.3.8.5. Canada: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • 10.4. Dermatology Drugs Market - Europe
    • 10.4.1. Europe: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
    • 10.4.2. Europe: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
    • 10.4.3. Europe: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.4.4. Europe: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 10.4.5. Europe: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.4.6. Dermatology Drugs Market - UK
      • 10.4.6.1. UK: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.4.6.2. UK: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.4.6.3. UK: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.6.4. UK: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.4.6.5. UK: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.4.7. Dermatology Drugs Market - France
      • 10.4.7.1. France: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.4.7.2. France: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.4.7.3. France: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.7.4. France: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.4.7.5. France: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.4.8. Dermatology Drugs Market - Germany
      • 10.4.8.1. Germany: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.4.8.2. Germany: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.4.8.3. Germany: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.8.4. Germany: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.4.8.5. Germany: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.4.9. Dermatology Drugs Market - Italy
      • 10.4.9.1. Italy: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.4.9.2. Italy: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.4.9.3. Italy: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.9.4. Italy: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.4.9.5. Italy: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.4.10. Dermatology Drugs Market - Spain
      • 10.4.10.1. Spain: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.4.10.2. Spain: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.4.10.3. Spain: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.10.4. Spain: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.4.10.5. Spain: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.4.11. Dermatology Drugs Market - Netherlands
      • 10.4.11.1. Netherlands: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.4.11.2. Netherlands: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.4.11.3. Netherlands: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.11.4. Netherlands: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.4.11.5. Netherlands: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.4.12. Dermatology Drugs Market - Russia
      • 10.4.12.1. Russia: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.4.12.2. Russia: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.4.12.3. Russia: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.12.4. Russia: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.4.12.5. Russia: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.4.13. Dermatology Drugs Market - Rest of Europe
      • 10.4.13.1. Rest of Europe: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.4.13.2. Rest of Europe: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.4.13.3. Rest of Europe: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.13.4. Rest of Europe: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.4.13.5. Rest of Europe: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • 10.5. Dermatology Drugs Market - Asia Pacific
    • 10.5.1. Asia Pacific: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
    • 10.5.2. Asia Pacific: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
    • 10.5.3. Asia Pacific: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.5.4. Asia Pacific: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 10.5.5. Asia Pacific: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.5.6. Dermatology Drugs Market - China
      • 10.5.6.1. China: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.5.6.2. China: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.5.6.3. China: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.6.4. China: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.5.6.5. China: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.5.7. Dermatology Drugs Market - India
      • 10.5.7.1. India: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.5.7.2. India: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.5.7.3. India: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.7.4. India: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.5.7.5. India: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.5.8. Dermatology Drugs Market - Malaysia
      • 10.5.8.1. Malaysia: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.5.8.2. Malaysia: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.5.8.3. Malaysia: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.8.4. Malaysia: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.5.8.5. Malaysia: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.5.9. Dermatology Drugs Market - Japan
      • 10.5.9.1. Japan: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.5.9.2. Japan: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.5.9.3. Japan: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.9.4. Japan: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.5.9.5. Japan: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.5.10. Dermatology Drugs Market - Indonesia
      • 10.5.10.1. Indonesia: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.5.10.2. Indonesia: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.5.10.3. Indonesia: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.10.4. Indonesia: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.5.10.5. Indonesia: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.5.11. Dermatology Drugs Market - South Korea
      • 10.5.11.1. South Korea: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.5.11.2. South Korea: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.5.11.3. South Korea: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.11.4. South Korea: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.5.11.5. South Korea: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.5.12. Dermatology Drugs Market - Australia
      • 10.5.12.1. Australia: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.5.12.2. Australia: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.5.12.3. Australia: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.12.4. Australia: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.5.12.5. Australia: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.5.13. Dermatology Drugs Market - Rest of Asia Pacific
      • 10.5.13.1. Rest of Asia Pacific: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.5.13.2. Rest of Asia Pacific: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.5.13.3. Rest of Asia Pacific: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.13.4. Rest of Asia Pacific: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.5.13.5. Rest of Asia Pacific: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • 10.6. Dermatology Drugs Market - Middle East & Africa
    • 10.6.1. Middle East & Africa: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
    • 10.6.2. Middle East & Africa: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
    • 10.6.3. Middle East & Africa: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.6.4. Middle East & Africa: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 10.6.5. Middle East & Africa: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.6.6. Dermatology Drugs Market - Saudi Arabia
      • 10.6.6.1. Saudi Arabia: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.6.6.2. Saudi Arabia: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.6.6.3. Saudi Arabia: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.6.4. Saudi Arabia: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.6.6.5. Saudi Arabia: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.6.7. Dermatology Drugs Market - UAE
      • 10.6.7.1. UAE: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.6.7.2. UAE: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.6.7.3. UAE: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.7.4. UAE: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.6.7.5. UAE: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.6.8. Dermatology Drugs Market - Israel
      • 10.6.8.1. Israel: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.6.8.2. Israel: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.6.8.3. Israel: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.8.4. Israel: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.6.8.5. Israel: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.6.9. Dermatology Drugs Market - South Africa
      • 10.6.9.1. South Africa: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.6.9.2. South Africa: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.6.9.3. South Africa: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.9.4. South Africa: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.6.9.5. South Africa: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.6.10. Dermatology Drugs Market - Rest of Middle East & Africa
      • 10.6.10.1. Rest of Middle East & Africa: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.6.10.2. Rest of Middle East & Africa: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.6.10.3. Rest of Middle East & Africa: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.10.4. Rest of Middle East & Africa: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.6.10.5. Rest of Middle East & Africa: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • 10.7. Dermatology Drugs Market - Latin America
    • 10.7.1. Latin America: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
    • 10.7.2. Latin America: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
    • 10.7.3. Latin America: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.7.4. Latin America: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 10.7.5. Latin America: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.7.6. Dermatology Drugs Market - Mexico
      • 10.7.6.1. Mexico: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.7.6.2. Mexico: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.7.6.3. Mexico: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.7.6.4. Mexico: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.7.6.5. Mexico: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.7.7. Dermatology Drugs Market - Brazil
      • 10.7.7.1. Brazil: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.7.7.2. Brazil: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.7.7.3. Brazil: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.7.7.4. Brazil: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.7.7.5. Brazil: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.7.8. Dermatology Drugs Market - Argentina
      • 10.7.8.1. Argentina: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.7.8.2. Argentina: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.7.8.3. Argentina: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.7.8.4. Argentina: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.7.8.5. Argentina: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 10.7.9. Dermatology Drugs Market - Rest of Latin America
      • 10.7.9.1. Rest of Latin America: Dermatology Drugs Market, by Therapy, 2020-2034 (USD Billion)
      • 10.7.9.2. Rest of Latin America: Dermatology Drugs Market, by Type, 2020-2034 (USD Billion)
      • 10.7.9.3. Rest of Latin America: Dermatology Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.7.9.4. Rest of Latin America: Dermatology Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 10.7.9.5. Rest of Latin America: Dermatology Drugs Market, by Drug Class, 2020-2034 (USD Billion)

11. Competitive Landscape

  • 11.1. Expansion and Acquisition Analysis
    • 11.1.1. Expansion
    • 11.1.2. Acquisitions
  • 11.2. Partnerships/Collaborations/Agreements/Exhibitions

12. Company Profiles

  • 12.1. AbbVie
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Benchmarking
    • 12.1.4. Recent Development
  • 12.2. Amgen
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Benchmarking
    • 12.2.4. Recent Development
  • 12.3. Bayer
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Benchmarking
    • 12.3.4. Recent Development
  • 12.4. Bristol-Myers Squibb
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Benchmarking
    • 12.4.4. Recent Development
  • 12.5. Eli Lilly and Company
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Benchmarking
    • 12.5.4. Recent Development
  • 12.6. Galderma
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Benchmarking
    • 12.6.4. Recent Development
  • 12.7. GlaxoSmithKline
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Benchmarking
    • 12.7.4. Recent Development
  • 12.8. Johnson & Johnson
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Benchmarking
    • 12.8.4. Recent Development
  • 12.9. L'Oreal
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Benchmarking
    • 12.9.4. Recent Development
  • 12.10. Meda Pharmaceuticals
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Benchmarking
    • 12.10.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제